Dr Peter McCullough Early Treatment Protocol (2023)
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals.
|McCullough et al. Reviews in Cardiovascular Medicine, 2020|
|McCullough Protocol 2022|
The current Omicron infection is characteristically mild with limited pulmonary and systemic involvement. For those who are having second and third infections it will be even more mild often indistinguishable from the common cold. All of the agents mentioned in this stack have reasonable supportive evidence. The therapeutic aims are to address viral replication, inflammation, and thrombosis.
The community standard of care for COVID-19 was developed by doctors in the field who learned how to treat the infection using their clinical judgement and available sources of evidence—not by government agencies, state medical boards, or royal colleges of physicians. Having nearly three years of experience in ambulatory management, Dr. McCullough has learned from experts around the globe that no single drug is necessary nor sufficient to treat COVID-19. Yes, that means that the syndrome can be treated without antiviral agents as reported by Dr. Barrientos (R) in El Salvador and Dr. Chetty in South Africa (R).
“Hydroxychloroquine far and away made the biggest difference,” McCullough commented. “It is not a cure alone, but it makes a giant difference.”
If a patient has known heart issues that put them at risk when taking hydroxychloroquine, McCullough offers ivermectin as an alternative.
He also believes the United States needs to immediately investigate the efficacy of favipiravir, which he says is being used successfully as a treatment in 30 countries around the world.
Along with hydroxychloroquine, McCullough’s protocol suggests a course of antibiotics, such as doxycycline or azithromycin, to help reduce the chance of secondary infections.
The risk of blood clotting is one of the most frightening aspects of the disease, McCullough acknowledged, and thus he has updated his earlier advice to increase the recommended dosage of aspirin to 325 mg daily.
“In a pandemic, we have to make a decision based on a reasonable chance of success,” he remarked. “We need major medical centers and medical boards to get on board [with early treatment].”
“I never thought I’d see the day where doctors are censored, and patients are kept from care,” McCullough grieved.
In December 2020, McCullough published an updated protocol, co-written with 56 other authors who also had extensive experience with treating COVID-19 outpatients. The article, "Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection," was published in the journal Reviews in Cardiovascular Medicine, of which McCullough is the editor-in-chief.
"That paper, today … is the most frequently downloaded paper from BET Journal," McCullough says. "It also is the basis for the American Association of Physician and Surgeons COVID early treatment guide.
We have evidence that the treatment guide has been downloaded and utilized millions of times. And it was part of the early huge kick that we had in ambulatory treatment at home towards the end of December into January, which basically crushed the U.S. curve.
We were on schedule to have 1.7 to 2.1 million fatalities in the United States, as estimated by the CDC and others. We cut it off at about 600,000. That still is a tragedy. I've testified that 85% of that 600,000 could have been saved if we would have had … the protocols in place from the start.
But suffice it to say, the early treatment heroes, and you're part of that team Dr. Mercola, has really made the biggest impact. We have saved millions of lives, spared millions and millions of hospitalizations, and in a sense, have brought the pandemic now to a winnowing close."
While the World Health Organization and national health agencies have rejected treatments suggested by doctors for lack of large-scale randomized controlled studies, McCullough and other doctors working the frontlines took an empiric approach. They looked for signals of benefit in the literature.
Dr. McCullough qualified that these views expressed are his own and do not necessarily reflect those of the institutions he’s associated with. His views may not be the answer to everything but it could be everything to you or your loved ones.
rumble.com/petermcculloughmd (Personal Website)
twitter.com/P_McCulloughMD (Personal Website)
It's important to note that the scientific community relies on evidence-based research to inform medical recommendations and guidelines. If you come across information about a treatment or approach that is not widely accepted or that lacks strong scientific evidence, it's a good idea to do your own research and consult with a healthcare professional before making any decisions.
- The Front Line COVID-19 Critical Care Alliance's (FLCCC's) prevention and early at-home treatment protocol. They also have a long-term management guidance for long-haul COVID-19 syndrome and post-vaccine syndrome protocol. You can find a listing of doctors who can prescribe ivermectin here.
- Zelenko Protocol
- Dr George Fareed and Dr Brian Tyson Early Treatment Protocol
- America's Frontline Doctors
- ACE inhibitor/ARB, together with carvedilol as tolerated to prevent/limit progressive decline in cardiac function. •
- Colchicine in patients with pericarditis – 0.6 mg/day orally; increase to 0.6 mg twice daily if required. Reduce dose if patients develop diarrhea. Monitor white blood cell count. Decrease dose with renal impairment. •
- Magnesium to reduce the risk of serious arrhythmias (see dosing above). •
- Coenzyme Q (CoQ) 200-400mg/day. (R, R, R)
- Omega-3 fatty acids – EPA/DHA 2-4 g/day (R). Increase dose slowly as tolerated. •
- Resveratrol/flavanoid combination for its anti-inflammatory and antioxidant properties. •
- Referral to a cardiologist or ER in case of persistent chest pain or other signs and symptoms of cardiac events are observed.
The cost of the Z-STACK vitamin cocktail is $55 per bottle for a one month supply.